Trade BVS stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
Bioventus Inc. Class A (BVS) is trading at US$12.91, up 2.22% today as of Sep 18, 16:00 EDT. The company has a market capitalisation of US$982.23M. Over the past 52 weeks, BVS has traded between US$6.26 and US$15.89. On Syfe you can trade BVS with $0 commission and add it to your watchlist.
| Previous close | US$12.63 |
|---|---|
| Market cap | US$982.23M |
| P/E ratio | 14.66 |
| 52-week range | US$6.26 – US$15.89 |
| Volume | 828.23K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Bioventus Inc. Class A
Bioventus, Inc. is a medical technology company, which focuses on developing and commercializing and proprietary orthobiologic products for the treatment of patients suffering from an array of musculoskeletal conditions. It operates through the following business segments: Active Healing Therapies-U.S, Active Healing Therapies-International, Surgical and BMP. The Active Healing Therapies-U.S and International offers two types of non-surgical products which are non-invasive exogen system for long bone stimulation for fracture healing and hyaluronic acid, or HA, viscosupplementation therapies for osteoarthritis pain relief. The Surgical segment offers a portfolio of advanced bone graft substitutes. The BMP segment comprises proprietary next-generation bone morphogenetic protein, or BMP. The company was founded on November 23, 2011 and is headquartered in Durham, NC.
Year: 2021
Barrington Adjusts Price Target on Bioventus to $18 From $14, Maintains Outperform Rating
Aug 6, 1:32 PM · MT Newswires
Bioventus Fiscal Q2 Adjusted Earnings, Revenue Rise; 2026 Guidance Reaffirmed
Aug 5, 2:16 PM · MT Newswires
-- GUIDANCE: (BVS) Bioventus Expects Full Year 2026 Revenue Range 600M-$610M, vs. FactSet Est of $605.3M
Aug 5, 11:40 AM · MT Newswires
-- GUIDANCE: (BVS) Bioventus Expects 2026 Adjusted EPS Range $0.75 - $0.79, vs. FactSet Est of $0.78
Aug 5, 11:39 AM · MT Newswires
-- Earnings Flash (BVS) Bioventus Inc. Reports Q2 Revenue $153.2M, vs. FactSet Est of $155.4M
Aug 5, 11:32 AM · MT Newswires
Bioventus Inc. Class A (BVS) stock is trading at US$12.91, +2.22% from the previous close of US$12.63.
The market cap for Bioventus Inc. Class A (BVS) stock is approximately US$982.23M.
The price-to-earnings ratio for Bioventus Inc. Class A (BVS) is 14.66, based on the latest reported earnings.
The 52-week high for Bioventus Inc. Class A (BVS) stock is US$15.89.
The 52-week low for Bioventus Inc. Class A (BVS) stock is US$6.26.
Bioventus Inc. Class A (BVS) does not currently pay a dividend.
Stay on top of BVS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
Popular Stocks in Singapore
